The Indian Patent Office on Thursday rejected US pharmaceutical giant Johnson and Johnson's application to extend its patent on a key tuberculosis treatment, allowing local companies to make cheaper generic versions.
Johnson and Johnson had applied to extend its patent on the drug bedaquiline until 2027 after it was challenged by two tuberculosis survivors in Mumbai in 2019